QY Research, Inc.

Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Size, Share, Development and Demand Forecast to 2025

QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.


City of Industry, CA -- (SBWIRE) -- 06/19/2018 -- This report studies the global Glucagon Like Peptide-1 (GLP-1) Agonists market status and forecast, categorizes the global Glucagon Like Peptide-1 (GLP-1) Agonists market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.

Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/341830/global-glucagon-like-peptide-1-glp-1-agonists-sales-market

The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.

The global Glucagon Like Peptide-1 (GLP-1) Agonists market is valued at 5240 million US$ in 2017 and will reach 14200 million US$ by the end of 2025, growing at a CAGR of 13.3% during 2018-2025.

The major players covered in this report

Novo Nordisk


Eli Lilly



Bristol-Myers Squibb



Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

United States




Southeast Asia


Request Sample Copy of Report@ https://www.qyresearch.com/sample-form/form/341830/global-glucagon-like-peptide-1-glp-1-agonists-sales-market

About QY Research
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert's resources (included energy automotive chemical medical ICT consumer goods etc.